A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Relapse after allogeneic stem cell transplantation (allo-SCT) remains the primary cause of treatment failure. A second SCT can result in long-term survival in a subset of patients, but the relapse rate remains high. We conducted a single-center, phase 1, modified 3 + 3 dose-escalation study of the f...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran, Misha C., Hasan, Yasmin, Wang, Amy, Yenice, Kamil, Partouche, Julien, Stock, Wendy, Larson, Richard A., Kosuri, Satyajit, LaBelle, James L., Kline, Justin, Riedell, Peter A., Artz, Andrew S., Weichselbaum, Ralph, Bishop, Michael R., Aydogan, Bulent, Liu, Hongtao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898602/
https://www.ncbi.nlm.nih.gov/pubmed/35851593
http://dx.doi.org/10.1182/bloodadvances.2022007530

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9898602/
https://www.ncbi.nlm.nih.gov/pubmed/35851593
http://dx.doi.org/10.1182/bloodadvances.2022007530

Ejemplares similares